Drug Trial Radar · NCT04115319
A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.
Last checked: Nov 20, 2026Latest source record: Dec 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
305
Actual
Start
Nov 21, 2019
Primary completion
Dec 30, 2022
Study completion Dec 30, 2022
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
- Sponsor type
- Industry
- First posted
- Oct 4, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A clinical study to evaluate the long-term safety and tolerability of an investigational drug in people with schizophrenia. This study is accepting male and female participants between 18 years old -65 years old who have been diagnosed with schizophrenia. This study will be conducted in approximately 50 study centers worldwide. The study will last approximately 57 weeks.
Conditions
- Schizophrenia
Interventions
SEP363856Drug
SEP-363856, 50mg, 75mg, 100mg, flexibly dosed once daily capsule
quetiapine XRDrug
quetiapine XR, 400, 600, 800 mg, flexibly dosed once daily capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs) Leading to Study DiscontinuationTime frame: From first dose of the study drug up to 7 days after last dose of study drug (Up to 53 weeks)
Locations
42 sites in 4 countries. Site status is shown where the registry gives one.
Research Site
Cerritos, California
Research Site
Oakland, California
Research Site
Oceanside, California
Research Site
San Diego, California
Research Site
Torrance, California
Research Site
Miami, Florida
Research Site
Miami Lakes, Florida
Research Site
Atlanta, Georgia
Research Site
Hoffman Estates, Illinois
Research Site
Lincolnwood, Illinois
Research Site
Shreveport, Louisiana
Research Site
St Louis, Missouri
Research Site
Las Vegas, Nevada
Research Site
Cedarhurst, New York
Research Site
Jamaica, New York
Research Site
Rochester, New York
Research Site
Charlotte, North Carolina
Research Site
North Canton, Ohio
Research Site
Brasov, Romania
Research Site
Bucharest, Romania
Research Site
Bucharest, Romania
Research Site
Bucharest, Romania
Research Site
Iași, Romania
Research Site
Arkhangelsk, Russia
Research Site
Moscow, Russia
Research Site
Omsk, Russia
Research Site
Saint Petersburg, Russia
Research Site
Saint Petersburg, Russia
Research Site
Saint Petersburg, Russia
Research Site
Saint Petersburg, Russia
Research Site
Saint Petersburg, Russia
Research Site
Smolensk, Russia
Research Site
Stavropol, Russia
Research Site
Tomsk, Russia
Research Site
Yaroslavl, Russia
Research Site
Yekaterinburg, Russia
Research Site
Ivano-Frankivsk, Ukraine
Research Site
Kharkiv, Ukraine
Research Site
Kyiv, Ukraine
Research Site
Smila, Ukraine
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.